Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554320 | 0.92 | KDM4E (0.53) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL11972779 | 0.86 | KDM4E (0.49) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL25143446 | 0.85 | CYP4F2 (0.58) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL11274523 | 0.84 | L3MBTL1 (0.50) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL1958849 | 0.84 | AKR1B1 (0.55) | KDM4ETSHRTDP1ALDH1A1POLB | |
| SCHEMBL2212572 | 0.82 | KDM4E (0.47) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL8851852 | 0.82 | KDM4E (0.47) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL2060361 | 0.82 | KDM4E (0.47) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL5842246 | 0.82 | CFD (0.48) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR | |
| SCHEMBL3927306 | 0.82 | KDM4E (0.47) | KDM4ECYP4F2CYP4A11SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440963-B2 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160008327-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint, Inc. | 2016-01-14 | — | — | US | disclosed |
| US-9174950-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9096555-B2 | Methods for treating vascular leak syndrome | AERPIO THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-8883832-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | KDM4E 1897/4885CYP4F2 1968/4885CYP4A11 3607/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | KDM4E 4392/4885CYP4F2 3671/4885CYP4A11 3536/4885 |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | KDM4E 4502/4885CYP4F2 4044/4885CYP4A11 1005/4885 |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | KDM4E 3591/4885CYP4F2 4303/4885CYP4A11 4317/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | KDM4E 2248/4885CYP4F2 1909/4885CYP4A11 2400/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | KDM4E 3689/4885CYP4F2 3892/4885CYP4A11 4059/4885 |
| US-20160008327-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | KDM4E 4691/4885CYP4F2 3222/4885CYP4A11 3213/4885 |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | KDM4E 1897/4885CYP4F2 1968/4885CYP4A11 3607/4885 |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | KDM4E 4626/4885CYP4F2 4255/4885CYP4A11 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.